You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 18, 2025

Drug Sales Trends for TRUVADA


✉ Email this page to a colleague

« Back to Dashboard


Drug Sales Revenue Trends for TRUVADA
Drug Units Sold Trends for TRUVADA

Annual Sales Revenues and Units Sold for TRUVADA

These sales figures are drawn from a US national survey of drug expenditures

Market Analysis and Sales Projections for Truvada

Introduction to Truvada

Truvada, developed by Gilead Sciences, is a crucial antiretroviral medication used for the treatment and prevention of HIV infection. It combines emtricitabine and tenofovir disoproxil fumarate (TDF) and has been a cornerstone in HIV management since its approval.

Market Dominance and Revenue

Truvada has been a significant revenue generator for Gilead Sciences, with annual sales reaching approximately $2.6 billion in the U.S. alone[2][5].

Generic Competition

The landscape for Truvada changed dramatically with the expiration of its patent in 2020. Generic versions of Truvada were introduced in March 2021, marking a significant shift in the market.

  • Multiple Generic Entrants: Within a short period, eight generic manufacturers entered the market, followed by two more, bringing the total to 11 competitors. This intense competition led to a more than 90% drop in the pharmacy acquisition cost of generic Truvada from the brand's list price[1].
  • Impact on Pricing: According to FDA research, when there are more than 10 generic producers of a drug, the median generic-to-brand price ratio can be as low as 1% to 2.2%. For Truvada, this would translate to a pharmacy acquisition cost of around $40 per month, but actual costs have been even lower, with some reports indicating costs below $1 per pill[1].

Transition to Descovy

In anticipation of generic competition, Gilead Sciences has been actively transitioning patients from Truvada to its newer drug, Descovy.

  • Conversion Rate: Gilead has been successful in converting a significant portion of Truvada patients to Descovy. Within two months of Descovy's FDA approval for PrEP, about 10% of Truvada patients were switched, with projections suggesting up to 50% to 60% could be switched by the time generic Truvada became widely available[5].
  • Clinical Advantages: Descovy offers better bone mineral density and renal safety outcomes compared to Truvada, which Gilead has highlighted to convince doctors and patients to make the switch[5].

Market Growth and Projections

Despite the challenges posed by generic competition, the overall HIV drugs market is expected to grow.

  • Global Market Size: The global HIV drugs market was valued at $34.13 billion in 2023 and is projected to grow to $58.24 billion by 2032, at a CAGR of 6.2%[3].
  • Pre-Exposure Prophylaxis (PrEP) Market: The PrEP market, which includes Truvada and Descovy, was valued at $2.6 billion in 2019 and is expected to grow to $3.3 billion by 2029, a 27% increase. However, this growth will be affected by generic erosion[4].
  • Regional Dominance: North America, particularly the U.S., dominates the HIV drugs market due to the high prevalence of HIV infection and increased awareness among the population. The U.S. accounted for over 85% of the HIV drug market in 2019 and is expected to maintain this dominance[3][4].

Impact of COVID-19

The COVID-19 pandemic had a temporary adverse impact on the HIV drugs market, including a decrease in sales volume for Truvada and other HIV medications. However, with prescription volumes returning to pre-pandemic levels, the market has seen strong growth post-pandemic[3].

Future Trends and Developments

  • Injectable Therapies: There is a growing trend towards the development of injectable therapies to improve patient adherence. Cabotegravir-based therapies are projected to account for a significant portion of the sales of injectable therapeutics in the HIV market by 2029[4].
  • Long-acting Suppression Antiretroviral Therapy: Research and development initiatives for long-acting suppression antiretroviral therapy are expected to be a vital trend in the coming years, contributing to market growth[3].

Key Takeaways

  • Generic Competition: The introduction of generic Truvada has significantly reduced its cost, but end-users may not see these savings due to various market dynamics.
  • Transition to Descovy: Gilead is actively transitioning patients from Truvada to Descovy, leveraging the newer drug's clinical advantages.
  • Market Growth: Despite generic competition, the global HIV drugs market is expected to grow, driven by increasing patient populations and new product launches.
  • Regional Dominance: North America, particularly the U.S., continues to dominate the HIV drugs market.
  • Future Trends: Injectable therapies and long-acting suppression antiretroviral therapy are expected to shape the future of the HIV drugs market.

FAQs

  1. When did generic versions of Truvada become available? Generic versions of Truvada became available in late March 2021, following the expiration of Gilead Sciences' patent in 2020[1][2].

  2. How has generic competition affected the cost of Truvada? The cost of generic Truvada has dropped more than 90% from the brand's list price, with some reports indicating costs below $1 per pill due to intense competition from multiple generic manufacturers[1].

  3. What is Gilead Sciences doing to mitigate the impact of generic Truvada? Gilead Sciences is transitioning patients from Truvada to its newer drug, Descovy, highlighting Descovy's better clinical outcomes to maintain market share[5].

  4. How is the COVID-19 pandemic affecting the HIV drugs market? The COVID-19 pandemic initially reduced sales volumes for HIV medications, including Truvada, but the market has seen strong growth post-pandemic as prescription volumes returned to pre-pandemic levels[3].

  5. What are the future trends in the HIV drugs market? Future trends include the development of injectable therapies to improve patient adherence and research into long-acting suppression antiretroviral therapy[3][4].

Sources

  1. 46brooklyn.com: Generic Truvada costs less than a dollar. Here's why you're likely paying much more.
  2. FiercePharma: Gilead's $3B Truvada will face generics a year early. Can Descovy save the day?
  3. Fortune Business Insights: HIV Drugs Market Size & Growth | Global Report [2024-2032]
  4. Managed Healthcare Executive: HIV Med Market To Reach $28B in 2029
  5. FiercePharma: Gilead's converting Truvada PrEP users to Descovy faster than expected, analyst says
Last updated: 2024-12-31

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.